NYSE MKT to Suspend Trading of Provectus Biopharma (PVCT) Shares; Will Move to Delist
- Discover Financial Services (DFS) Announces CEO Resignation
- Timken (TKR) Appoints Tarak Mehta as New CEO
- Crude Inventory Increases 3.2 Million Barrels
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Many senior Amazon employees won't get cash raises this year - Fortune
Provectus Biopharmaceuticals Announces Poster Presentation on PV-10 at European Society of Medical Oncology 2016 Congress Now Available Online
October 11, 2016 6:01 AM EDTPoster Updates Details of Studies of PV-10 as Single Agent Therapy and in Combination for Melanoma
KNOXVILLE, Tenn.--(BUSINESS WIRE)-- Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or the "Company), today announced that the poster presented at the European Society of Medical Oncology 2016 Congress is now available online.
Titled... More